FDA clears FemChec for fallopian tube occlusion testing [Yahoo! Finance]
Femasys Inc. (FEMY)
Company Research
Source: Yahoo! Finance
The 510(k) clearance is for FemCheck, Femasys' diagnostic device that delivers a controlled amount of contrast to fallopian tubes for examination of tubal status during ultrasound procedures. Used with an intrauterine catheter, the system utilises an alternating pattern of saline and air in a continuous stream of contrast media. While indicated for evaluation of fallopian tubes with or without the uterine cavity, the device's main use will likely be in conjunction with Femasys' birth control product, FemBloc. FemBloc is an implant delivered in-office as a biopolymer via balloon catheters. Once the biopolymer touches the tissue within the tubes, it solidifies, triggering wound healing and eventual scar tissue formation. The resulting scar tissue blocks the tubes while the biopolymer degrades and is expelled. Currently, women seeking permanent birth control only have surgery as an option. The procedure is called tubal ligation, which involves the surgical tying, cutting, or blo
Show less
Read more
Impact Snapshot
Event Time:
FEMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FEMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FEMY alerts
High impacting Femasys Inc. news events
Weekly update
A roundup of the hottest topics
FEMY
News
- Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic DevicesGlobeNewswire
- Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices [Yahoo! Finance]Yahoo! Finance
- Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic DevicesGlobeNewswire
- Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control [Yahoo! Finance]Yahoo! Finance
FEMY
Sec Filings
- 1/30/25 - Form 4
- 1/30/25 - Form 4
- 1/30/25 - Form 4
- FEMY's page on the SEC website